Silo Pharma Enters Asset Purchase Agreement, Issues 165,000 Shares

What Happened
Silo Pharma, Inc. announced on August 18, 2026 that it entered into an Asset Purchase Agreement with Parkview Consulting LLC under which the Company purchased certain software, technology, domain names and related intellectual property (the “Purchased Assets”). As consideration, Silo issued 165,000 shares of its common stock (par value $0.0001). The agreement is filed as Exhibit 10.1 to the Form 8-K.

Key Details

• Seller: Parkview Consulting LLC; Corwin Yu is the sole member/manager of the Seller and currently serves as lead strategic advisor on Silo’s Cryptocurrency Advisory Board (related-party connection).
• Consideration: 165,000 shares of common stock issued to the Seller.
• Lock-up: Shares are subject to a transfer restriction until the earlier of (i) 12 months after the effective date, (ii) a Change in Control, or (iii) the Company’s written consent. Transfers, sales, hedging, pledges or similar transactions are prohibited during the Lock Up Period without prior written consent.
• Protective provisions: The Agreement includes customary reps, warranties and covenants, and the Seller agreed to indemnify Silo for misrepresentations, breaches, third‑party IP infringement by the software, and acts of gross negligence, fraud or intentional misconduct.
• Reporting: The issuance is reported under Item 3.02 (unregistered sales of equity securities) on the Form 8-K.

Why It Matters
This filing documents a non‑cash acquisition of software and related IP in exchange for equity, which increases Silo’s outstanding shares by 165,000 and transfers specific technology assets to the company. The one‑year (or earlier upon change in control) lock‑up limits immediate resale of the issued shares, which can reduce near‑term downward pressure from the transaction. The involvement of Corwin Yu—an advisor to Silo—makes this a related‑party transaction and is disclosed for investor transparency; the Seller’s indemnities reduce certain legal and IP risks for Silo. Investors should note the nature and size of the consideration and the related‑party disclosure when assessing impact on share count and company resources.